[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Medical Center Ho Chi Minh City (UMC)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":433},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,74,103,127,152,178,204,231,254,277,301,332,361,386,410],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643952","early-labor-pre-marking-for-epidural-analgesia-ultrasound-vs-manual-palpation-100643952",false,"NCT07669441","Early Labor Pre-Marking for Epidural Analgesia: Ultrasound vs Manual Palpation","Efficacy of Ultrasound-Guided Versus Landmark-Based Epidural Labor Analgesia: A Randomized Clinical Trial.","Inclusion Criteria:\n\n* Parturients aged 18 years and older, with gestational age at 37 weeks or older.\n* Actively requesting epidural analgesia for labor pain management without any contraindication to the procedure.\n\nExclusion Criteria:\n\n* Parturients with spinal abnormalities or a history of spinal surgery.\n* Inability to visualize epidural landmarks under ultrasound imaging.\n* Parturients experiencing severe pain requiring immediate, emergent labor analgesia.","FEMALE","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if finding and marking the best spot on the back early in labor helps doctors perform epidural pain relief more successfully in pregnant women. Usually, epidural pain relief is requested when labor pain is already severe, which makes it hard for women to hold still. This makes it difficult to find the right needle spot, leading to more needle attempts\n\nThe main questions this study aims to answer are:\n\n* Does using ultrasound to mark the back early in labor (before severe pain starts) help the doctor place the needle correctly on first try without adjusting it?\n* Does this early marking method lower the number of needle attempts and the time it takes to finish the procedure? Researchers will compare marking the back using an ultrasound machine to the standard method of feeling the spine with hands. Both methods will be done early in the waiting room to avoid the challenges caused by severe pain. Importantly, neither the pregnant women nor the doctors performing the epidural will know which marking method was used. This design prevents personal beliefs or expectations from affecting the procedure, making the study results objective and trustworthy.\n\nParticipants will, if consented and participated in the study:\n\n* Have their lower back examined and marked by a doctor early in labor using either an ultrasound machine or the doctor's hands.\n* Receive an epidural pain relief in the delivery room when they request it. This will be done by a different doctor who does not know how the back was marked.\n* Answer short questions about their pain level and how happy they are with the procedure.",[26,27,28],"Labor Pain","Epidural Analgesia for Labour and Delivery","Neuraxial Ultrasound",[30,26,28,31,32,33,34,35],"Epidural Analgesia","Preprocedural Spinal Ultrasound","Anatomical Landmark Palpation","Obstetric Anesthesia","Regional Anesthesia","First-pass success","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":20},"2026-08-30",{"name":46,"class":47},"University Medical Center Ho Chi Minh City (UMC)","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100638297","effectiveness-of-enhanced-recovery-after-surgery-eras-protocols-for-arthroscopic-anterior-cruciate-ligament-reconstruction-in-an-ambulatory-surgery-setting-100638297","NCT07602231","Effectiveness of Enhanced Recovery After Surgery (ERAS) Protocols for Arthroscopic Anterior Cruciate Ligament Reconstruction in an Ambulatory Surgery Setting","Evaluation of Clinical Outcomes and Feasibility of Enhanced Recovery After Surgery (ERAS) Protocols for Arthroscopic Anterior Cruciate Ligament Reconstruction in an Ambulatory Surgery Setting: A Non-randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of anterior cruciate ligament (ACL) rupture with indication for primary arthroscopic reconstruction\n* Voluntary agreement to participate in the study and signing of the informed consent form\n\nExclusion Criteria:\n\n* Patients with concomitant knee pathologies requiring additional surgical procedures in the same session\n* Presence of contraindications for ambulatory (day) surgery\n* Failure to adhere to the scheduled follow-up visits","ALL",{"count":58,"type":20},115,[23],"The anterior cruciate ligament (ACL) is a critical component for maintaining knee stability by resisting anterior tibial translation and internal rotation. ACL rupture is one of the most common orthopedic injuries, with an estimated incidence of 70 cases per 100,000 people annually. Since its inception, arthroscopic anterior cruciate ligament reconstruction (AACLR) has proven to be the gold standard, providing excellent outcomes in terms of graft longevity, return to sports, and patient satisfaction. Modern medical trends are shifting toward day-surgery protocols, where patients are discharged within 24 hours without an overnight stay. This model is identified as a major factor in enhancing the quality of postoperative recovery and patient satisfaction.\n\nThe Enhanced Recovery After Surgery (ERAS) program utilizes evidence-based multimodal interventions to reduce surgical stress and accelerate functional recovery. While day-surgery for AACLR has been proven feasible globally, its implementation in Vietnam remains limited due to systemic barriers. At the University Medical Center Ho Chi Minh City, although ERAS has been applied since 2022, the average length of stay for AACLR is 2.57 days, indicating significant room for optimization. This study aims to evaluate the current compliance with ERAS and the effectiveness of fully implementing these protocols to enable a day-surgery model.\n\nThe research is designed in two phases, including a descriptive cohort and a clinical intervention. The intervention focuses on 06 core ERAS measures:\n\n* Comprehensive preoperative counseling and education.\n* Reducing preoperative fasting by using Maltodextrin 2 hours before surgery.\n* Standardized anesthesia combined with local infiltration analgesia (LIA).\n* Multimodal analgesia to minimize opioid consumption.\n* Early drainage removal within 6-8 hours postoperatively.\n* Immediate postoperative rehabilitation starting in the recovery unit. Effectiveness will be measured through various outcomes: the quality of early recovery via the QoR-15 score, mechanical knee function via the Lysholm Knee Scoring Scale (LKSS), and health-related quality of life via the EQ-5D-5L. Furthermore, a cost-effectiveness analysis (CEA) will be conducted using the Incremental Cost-Effectiveness Ratio (ICER). The study expects to demonstrate that strict ERAS adherence makes day-surgery AACLR feasible, reduces hospital-acquired infections, optimizes operating room productivity, and lessens the financial burden on both patients and the healthcare system.",[62,63,64],"Anterior Cruciate Ligament Rupture","Enhanced Recovery After Surgery (ERAS) Protocol","Ambulatory Surgery","NOT_YET_RECRUITING","2026-05-22",{"date":68,"type":40},"2026-05-28",{"date":70,"type":20},"2026-05-18",{"date":72,"type":20},"2027-06-30",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100592972","evaluation-of-the-efficacy-and-safety-of-gelsectan-in-the-treatment-of-diarrhea-predominant-irritable-bowel-syndrome-100592972","NCT07000383","Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome","Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome at University Medical Center Ho Chi Minh City, Vietnam: a Randomized, Open-label Clinical Trial","GELIBS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of IBS-D based on the Rome IV criteria,8 including:\n\n  * Recurrent abdominal pain occurring at least one day per week in the last three months, associated with at least two of the following: related to defecation, associated with a change in stool frequency, or associated with a change in stool form. These criteria must have been present during the last three months, with symptom onset at least six months prior to diagnosis;\n  * More than 25% of bowel movements with stool types 6 or 7 and less than 25% with stool types 1 or 2 according to the Bristol Stool Form Scale.\n* Signed informed consent for study participation\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Known allergy to any component of the study medication\n* Diagnosed with diabetes mellitus\n* Patients with severe comorbidities or psychiatric disorders that impair their ability to complete questionnaires or attend follow-up visits",{"count":83,"type":20},90,[23],"This clinical study aims to investigate the effectiveness and safety of Gelsectan, a treatment containing xyloglucan, in adults diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D) in Vietnam. IBS-D is a common digestive disorder that causes frequent diarrhea along with abdominal pain and bloating, significantly affecting patients' daily life and wellbeing.\n\nThe main goal of the study is to determine whether Gelsectan can reduce the severity of symptoms such as diarrhea, abdominal discomfort, and bloating, and improve patients' quality of life. Participants will be randomly assigned to receive either Gelsectan alone, Gelsectan combined with an antispasmodic medication, or antispasmodic medication alone. The treatment will last for two months, with regular monitoring of symptom changes and any side effects.\n\nThe investigators hypothesize that Gelsectan treatment will lead to better symptom relief and quality of life compared to standard antispasmodic treatment. The study will also carefully observe the safety profile of Gelsectan during the treatment period.\n\nResults from this study will provide important information about the potential benefits and risks of Gelsectan for Vietnamese patients with IBS-D and may contribute to improving treatment options for this condition in Vietnam.",[87,88],"Diarrhea-predominant Irritable Bowel Syndrome","Irritable Bowel Syndrome of Diarrhea Type (IBS-D)",[90,91,92,93,94,95,80],"Irritable Bowel Syndrome","Gelsectan","Diarrhea-Predominant Irritable Bowel Syndrome","IBS-D","Irritable Bowel Syndrome of Diarrhea type","Xyloglucan",{"date":97,"type":40},"2026-05-27",{"date":99,"type":40},"2025-06-15",{"date":101,"type":20},"2026-07-31",{"name":46,"class":47},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100584269","prognostic-value-of-right-ventricular-pulmonary-arterial-coupling-assessed-by-echocardiography-in-septic-patients-100584269","NCT06887140","Prognostic Value of Right Ventricular-pulmonary Arterial Coupling Assessed by Echocardiography in Septic Patients","Prognostic Value of Right Ventricular-pulmonary Arterial Coupling Assessed by Echocardiography in Septic Patients: A Prospective Observational Study","Inclusion Criteria:\n\n* Diagnosed with sepsis,\n* Received treatment in the Intensive Care Unit (ICU) at the University Medical Center at Ho Chi Minh City during the study period.\n\nExclusion Criteria:\n\n* Pregnancy,\n* History of right ventricular myocardial infarction,\n* Acute coronary syndrome within the past 1 week,\n* Valvular heart diseases or a history of valve replacement surgery,\n* Congenital heart diseases or conditions involving intracardiac shunts.",{"count":111,"type":20},215,"OBSERVATIONAL","Sepsis and septic shock are common clinical conditions, representing a significant healthcare challenge due to their high mortality rates and increasing incidence. Sepsis-induced cardiomyopathy is a frequent complication, occurring in up to 44% of septic patients. This condition is associated with a two- to three-fold increase in mortality. Although sepsis-induced cardiomyopathy is typically diagnosed via echocardiography to assess left ventricular systolic function, both ventricles may be affected. Several studies have demonstrated that right ventricular dysfunction (RVD)\u002F right ventricular failure (RVF) was prevalent in sepsis and septic shock, with significant implications for prognosis and mortality.\n\nThe right ventricle (RV) has a distinct anatomical structure and function compared to the left ventricle, characterized by its high sensitivity to afterload variations. Even minor increases in afterload can severely impair RV contractile function. Meanwhile, septic patients often experience hypoxemic respiratory failure and require mechanical ventilation. This condition generates hypoxia-induced pulmonary vasoconstriction, which, combined with positive pressure ventilation, leads to increased pulmonary vascular resistance and elevated pulmonary arterial pressure. Additionally, systemic vasodilation reduces RV preload, while septic shock and vasopressor use further compromise right coronary perfusion, exacerbating RV contractile dysfunction. Consequently, simultaneous assessment of RV contractility and its afterload is crucial in septic patients.\n\nTricuspid annular plane systolic excursion (TAPSE) is a widely used echocardiographic parameter for evaluating RV systolic function. Pulmonary artery systolic pressure (sPAP) reflects RV afterload and can be estimated in the presence of tricuspid regurgitation. Recently, the TAPSE\u002FsPAP ratio has been proposed as a clinical tool to assess right ventricle-pulmonary artery (RV-PA) coupling. This index has been shown to be associated with mortality in patients with pulmonary hypertension and heart failure. Several studies have been conducted to evaluate RV-PA coupling in sepsis and septic shocks, but these studies have limitations in terms of study design and patient selection.\n\nIn Vietnam, the issues of RVD\u002FRVF in sepsis\u002Fseptic shock have not been thoroughly investigated. Le Minh Khoi and colleagues reported that the incidence of reduced RV strain in septic patients was as high as 55.1%. Currently, no studies have specifically evaluated RV function, nor have any studies assessed RV-PA coupling in septic patients.",[115],"Sepsis",[115,117,118,119,120],"Septic shock","Sepsis-induced Cardiomyopathy","Right ventricle-pulmonary artery coupling","Echocardiography",{"date":97,"type":40},{"date":123,"type":40},"2025-04-16",{"date":125,"type":20},"2027-02",{"name":46,"class":47},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":48},"100638518","function-of-beta-cells-in-early-onset-diabetes-mellitus-100638518","NCT07574138","Function of Beta Cells in Early-onset Diabetes Mellitus","Comparison of Beta Cell Functional Changes in Patients With Early-onset Type 2 Diabetes Mellitus and Those With Typical Onset","Inclusion Criteria:\n\n* The patient is diagnosed with Type 2 Diabetes Mellitus according to the ADA 2024 criteria (Fasting Glucose ≥ 126 mg\u002Fdl, or Glucose after 2 hours of an Oral Glucose Tolerance Test ≥ 200 mg\u002Fdl, or HbA1C ≥ 6.5%, or with typical symptoms accompanied by any Glucose ≥ 200 mg\u002Fdl).\n* The duration of Type 2 Diabetes Mellitus does not exceed 10 years.\n* Classification by age of onset: Early onset group (\\\u003C 40 years) and typical onset group (≥ 40 years).\n* At least 6 months without the need for insulin and no recorded episodes of diabetic ketoacidosis since the time of diagnosis.\n* For the early-onset group: Autoantibodies (Anti-GAD, ICA) are negative and fasting C-peptide levels are \\> 0.6 nmol\u002FL.\n* The patient consents to participate in the study and signs the informed consent document.\n\nExclusion Criteria:\n\n* Pregnant women or patients with acute illnesses at the time of assessment.\n* The patient has been diagnosed with or exhibits characteristics suggestive of Type 1 Diabetes Mellitus (such as a history of ketoacidosis, C-peptide \\\u003C 0.2 nmol\u002FL).\n* Secondary diabetes mellitus due to pancreatic disorders (pancreatitis, pancreatic tumors, pancreatic resection), due to medications (glucocorticoids), or due to other endocrine disorders (Cushing's syndrome, hyperthyroidism, acromegaly).\n* Severe renal failure with an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n* Use of medications that affect beta cell function or complications such as prolonged high-dose corticosteroids, immunosuppressive agents, or chemotherapy.\n* Not of Vietnamese ethnicity.\n* Non-compliance with treatment guidelines or failure to attend scheduled follow-up appointments.",{"count":135,"type":20},296,"* Research objectives: Evaluate and compare the clinical and paraclinical characteristics, complications, as well as the changes in beta cell function and HbA1C levels between two patient groups over a one-year follow-up period.\n\n  +Research design: This is a prospective cohort study, monitoring patients at 3, 6, 9, and 12 months.\n* Study Population and Sample Size: The study is planned to be conducted on 296 Vietnamese patients (accounting for a 20% dropout rate) who are being examined at the University of Medicine and Pharmacy Hospital in Ho Chi Minh City.\n* Key Evaluation Indicators: The function of beta cells and insulin resistance status are measured through the indices of HOMA-B, HOMA-IR, fasting C-peptide levels, and HbA1C levels.\n* Time and location: The study will be conducted from February 2025 to February 2028 at the Endocrinology Clinic, University Medical Center Ho Chi Minh City.",[138,139],"Type 2 Diabetes Mellitus (T2DM)","Beta Cell Function",[141,142,143],"Early-onset type 2 diabetes mellitus","Beta cell function","C-peptide","2026-05-01",{"date":146,"type":40},"2026-05-07",{"date":148,"type":40},"2025-02-24",{"date":150,"type":20},"2028-02",{"name":46,"class":47},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100634967","mechanical-bowel-preparation-in-laparoscopic-right-hemicolectomy-with-intracorporeal-anastomosis-100634967","NCT07546565","Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis","The Role of Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Totally Intracorporeal Anastomosis for Colon Cancer: A Randomized Controlled Trial","UMC-Colprep","Inclusion Criteria:\n\n* Patients with colon cancer stage I-III according to the TNM classification\n* Patients undergoing elective right hemicolectomy or extended right hemicolectomy with totally intracorporeal anastomosis at University Medical Center Ho Chi Minh City\n* Postoperative histopathological confirmation of adenocarcinoma\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery\n* Contraindications to mechanical bowel preparation (e.g., bowel obstruction, subobstruction, bowel perforation, or peritumoral abscess)\n* Contraindications to laparoscopic surgery (American Society of Anesthesiologists \\[ASA\\] physical status IV or V) or to intracorporeal anastomosis\n* Distant metastasis at the time of surgery (stage IV according to the TNM classification)\n* Recurrent colon cancer after prior surgery\n* Synchronous primary malignancies in other organs\n* Patients undergoing palliative surgery or surgery for tumor-related complications (non-curative intent)\n* Inability to complete follow-up or be contacted",{"count":161,"type":20},74,[23],"This study is a randomized controlled trial conducted at University Medical Center Ho Chi Minh City to evaluate the role of mechanical bowel preparation (MBP) in patients undergoing laparoscopic right hemicolectomy with totally intracorporeal anastomosis for colon cancer.\n\nMechanical bowel preparation is commonly used before colorectal surgery to reduce bowel contents and potentially decrease the risk of postoperative infections. However, its benefit remains controversial, particularly in intracorporeal anastomosis, where intra-abdominal contamination may influence surgical outcomes.\n\nIn this study, eligible patients will be randomly assigned to one of two groups: with or without mechanical bowel preparation before surgery. The study aims to compare intraoperative events, postoperative complications, and recovery outcomes between the two groups.\n\nThe primary outcome is the rate of surgical site infection (SSI) within 30 days after surgery. Secondary outcomes include intraoperative fecal contamination, anastomotic leakage, postoperative ileus, operative time, and recovery parameters such as time to first bowel movement and length of hospital stay.\n\nThe findings of this study are expected to clarify the role of mechanical bowel preparation in reducing postoperative infections and improving surgical outcomes in patients undergoing laparoscopic right hemicolectomy.",[165],"Colon Cancer",[167,168,169],"Colon cancer","Surgical site infection","Mechanical bowel preparation","2026-04-16",{"date":172,"type":40},"2026-04-22",{"date":174,"type":40},"2025-09-01",{"date":176,"type":20},"2027-10-31",{"name":46,"class":47},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":48},"100575144","cytoreductive-gastrectomy-after-systemic-therapy-versus-systemic-therapy-alone-for-limited-metastasis-gastric-cancer-100575144","NCT06768463","Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer","Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer: An Open-label Randomized Controll Trial","CYGAS-GC","Inclusion criteria General criteria\n\n* Age 18-75\n* GCLM detected on surgical exploration and demonstrated by histology or cytology\n* Localized peritoneal carcinomatosis (P1 or P2 score), according to the classification of the Japanese Research Society for Gastric Cancer\n* Liver metastasis lesions of maximum diameter ≤5 cm\n* Para-aortic lymph node metastasis below the coeliac axis or above the inferior mesenteric artery (lymph node 16a1\u002Fb2 of maximum diameter≥1cm)\n* Bilateral or unilateral Krukenberg tumors were allowed and considered 1 incurable organ site\n* The accepted patient has two metastases\n* Baseline Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 1\n* Basic laboratory tests demonstrating adequate bone marrow function (neutrophil count \\> 1500mm3, haemoglobin \\> 8g\u002FdL, platelet count \\> 100,000\u002Fmm3), adequate liver function (bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within upper limits of normal), adequate renal function (serum creatinine within the upper limit of normal)\n* Expected survival \\> 3 months\n* Able to tolerate enteral nutrition and adequate mental capacity to give informed consent\n* Completed 4 cycles of first-line standard-of systemic therapy\n* Repeat diagnostic laparoscopy after first-line treatment prior to randomization demonstrating feasible resection.\n\nEligibility criteria for resection \\& extent of proposed resection\n\n* Staging scans (cross-sectional imaging) demonstrating no extra metastases (lung, bone,...)\n* Cross-sectional imaging demonstrating no local progression of PM\n* PCI score \\\u003C12\n* Cytology +ve alone (no gross PM) permissible for enrolment\n* Feasible R0 resection (reasonable chance of negative margins on histology)\n* Feasible D1, D1+ or D2 lymphadenectomy\n\nExclusion criteria\n\n* Any extra-abdominal metastasis at diagnosis or during systemic treatment.\n* Past history of malignancy other than gastric cancer diagnosed in the last 5 years except for basal cell carcinoma of skin or preinvasive cancer of cervix\n* Patients in the reproductive age who declined to use an adequate means of contraception\n* Significant disease or conditions which, in the investigator's opinion, would exclude patient from the study\n* Uncontrolled concurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant and lactating females\n* Prior surgical treatment for GC involving resection\n* Clinical or radiological progression during 1st line systemic treatment\n\n  * Patients with radiological progression of LM (determined by RECIST criteria) to be excluded as disease is likely not responding well to 1st line treatment.\n  * Patients with clinical progression of LM as defined by increasing ascites requiring intervention (ascitic tap\u002Fdrain, hospital admission etc) or causing significant symptoms to the patient (tense distended abdomen, early satiety, shortness of breath etc).\n\n    * Ascites volume as a reflection of disease control is difficult to assess and quantify or a reflection of disease progression. (15)\n* Any patient deemed unresectable or requiring extensive resection beyond procedure approved in the study protocol\n\n  * PCI \\> 12\n  * Extensive bowel \u002F mesentery involvement requiring \\>2 separate \u002F non-contiguous small or large bowel resections in addition to the gastrectomy\n  * Involvement of the head of pancreas or bile duct\n  * PM or nodal disease in the hepatoduodenal ligament\n  * Involvement of major vascular structures\n  * Involvement of esophagus precluding a reasonable chance of R0 resection by transhiatal approach Withdrawal Criteria\n* Patient decides to withdraw from the study, or\n* The investigator concludes that it is in the patient's best interest to discontinue study treatment.","75 Years",{"count":188,"type":20},250,[23],"The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide.\n\nHypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.",[192,193,194,195],"Metastatic Gastric Cancer","Gastric Cancer","Systemic Therapy","Cytoreductive Gastrectomy","2025-08-20",{"date":198,"type":40},"2025-08-27",{"date":200,"type":40},"2025-08-01",{"date":202,"type":20},"2027-12-10",{"name":46,"class":47},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":186,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},"100561832","vietnamese-rapid-acceleration-protocol-for-intensifying-drug-therapy-in-heart-failure-with-reduced-ejection-fraction-100561832","NCT06595290","Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction","VN-RAPID","Inclusion Criteria:\n\n1. Hospital admission with diagnosis of acute heart failure assessed by clinical signs and symptoms of congestion and radiographic, biological tests (if admitted with acute coronary syndrome, required at least Killip class II or clear evidence of congestion on admission assessed by chest x-ray or lung ultrasound and\u002For pulmonary congestion requiring intravenous treatment)\n2. Female or male patients ≥ 18 years old\n3. At randomization:\n\n   1. Systolic blood pressure \\> 90 mmHg (at least 2 measurements on 2 different occasions) and\n   2. Heart rate ≥ 60 bpm (at least 2 measurements on 2 different occasions) and\n   3. Serum potassium ≤ 5.0 mmol\u002FL\n4. Left ventricular ejection fraction (LVEF) ≤ 40% assessed locally by Simpson's Biplane method via echocardiography (if multiple LVEF measurements, the last one performed prior to randomization should be considered as the qualifying measurement)\n5. Persistent congestion at the time of randomization with pre-discharge NT-proBNP ≥ 1500 ng\u002FL\n6. HFrEF medications at randomization:\n\n   1. ≤ ¼ RASi\u002FARNi target dose and\n   2. ≤ ¼ beta-blocker target dose and\n   3. ≤ ½ MRA dose\n7. Obtained written informed consent form\n\nExclusion Criteria:\n\n1. Clearly documented intolerance to high doses of RASi\u002FARNi or beta-blockers\n2. Absolute contraindication to usage of RASi\u002FARNi or beta-blocker or MRA or SGLT2i as per ESC 2021\u002FACC 2022 Heart failure guideline\n3. LVEF \\>40% assessed by echocardiography on the latest measurement prior to discharge\n4. Renal disease or eGFR \\< 30 mL\u002Fmin\u002F1.73m2 (as estimated by the CKD-EPI 2021 or the simplified MDRD) at Screening or history of dialysis.\n5. Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1\\< 1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.\n6. Implantation of cardiac resynchronization device or underwent coronary artery bypass graft surgery within 3 months\n7. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous coronary intervention (PCI), within 1 month prior to Screening.\n8. AHF triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation\u002Fflutter with sustained ventricular response \\>130 beats per minute, or bradycardia with sustained ventricular arrhythmia \\<45 beats per minute), infection, severe anemia, pulmonary embolism, exacerbation of COPD, planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.\n9. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.\n10. History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.\n11. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.\n12. Presence at Screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion of the left ventricular outflow tract.\n13. Active infection at any time during the AHF hospitalization prior to Randomization based on abnormal temperature and elevated WBC or need for intravenous antibiotics.\n14. Stroke or TIA within the 3 months prior to Screening.\n15. Primary liver disease considered to be life threatening.\n16. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \\< 6 months.\n17. Prior (defined as less than 30 days from screening) or current enrollment in a CHF trial or participation in an investigational drug or device study within the 30 days prior to screening\n18. Discharge for the AHF hospitalization anticipated to be \\> 14 days from admission, or to a long-term care facility. Randomization must occur within 12 days following admission and at within 2 days prior to anticipated discharge.\n19. Inability to comply with all study requirements, due to major comorbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures\n20. Pregnant or nursing (lactating) women.",{"count":212,"type":20},500,[23],"VN-RAPID is an open-label, multicenter, randomized controlled trial evaluating the safety and efficacy of in-hospital initiation and rapid up-titration of four-pillar therapy for hospitalized Asian patients with acute heart failure (AHF) and reduced ejection fraction (HFrEF). The study compares a standardized protocol of intensified treatment (high-intensity care arm) with usual care in patients with elevated NT-proBNP levels who are not on optimal HFrEF medications. The high-intensity care arm involves initiation of all four pillars of HFrEF therapy (RAS inhibitor, beta-blocker, MRA, and SGLT2i) before discharge, followed by a structured 6-week outpatient up-titration process with frequent follow-ups. The study aims for 75% of target doses for RAS inhibitors and beta-blockers, considering the lower blood pressure tendency in Asian populations. Participants will be followed for 180 days to assess clinical outcomes.",[216,217],"Acute Heart Failure (AHF)","Acute Heart Failure With Reduced Ejection Fraction",[219,220,221,222],"HFrEF","STRONG-HF","Acute heart failure","Rapid uptitration","2025-07-31",{"date":225,"type":40},"2025-08-05",{"date":200,"type":40},{"date":228,"type":20},"2029-01-01",{"name":46,"class":47},4,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":56,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":48},"100600690","application-of-real-time-ultrasound-guidance-in-thoracic-epidural-catheter-placement-100600690","NCT07100769","Application of Real-time Ultrasound Guidance in Thoracic Epidural Catheter Placement","Application of Real-time Ultrasound-guidance in Thoracic Epidural Catheter Placement on Patients Undergoing Major Abdominal Thoracic or Abdominal Surgeries","Inclusion Criteria:\n\n* Patients are scheduled for major thoracic or abdominal surgeries who have consented to thoracic epidural analgesia\n\nExclusion Criteria:\n\n* Patients have contraindications for central neuraxial analgesia, allergic to medications used in the study, unable to cooperate due to cognitive impairment or behavioral limitations, spinal deformities or other spinal pathologies.","16 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to assess the success rate of real-time ultrasound-guided thoracic epidural catheter placement at the first attempt in patients who will undergo thoracic or abdominal surgeries. The main aims are to:\n\nAssess the success rate of first-attempt thoracic epidural catheter placement. Assess the procedure duration of real-time ultrasound-guided epidural catheter placement Participants will be managed according to the following protocol The patient will have real-time ultrasound guided catheter placement using paramedian-cross view performed by an attending anesthesiologist who is also an investigator After being secured, the thoracic epidural catheter is tested with 3ml lidocaine 2% At 30 minutes after the test dose, the level of sensory block is assessed by using an ice cube to test cold sensation on the skin according to dermatome Epidural analgesia is initiated by a 0.1ml\u002Fkg bolus and maintained by continuous infusion of solution 0.1% ropivacaine combined with 1mcg\u002Fml fentanyl during the surgery At the end of the surgery, the patients will paracetamol 15miligram per kilogram and nefopam 20 milligrams, the patient will receive another epidural bolus dose of 0,1ml\u002Fkg ropivacaine 0.1% combined with fentanyl 1mcg\u002Fml After the surgery, the patient will receive paracetamol 15miligram per kilogram every 8 hours, nefopam 20mg every eight hours, continuous epidural infusion at rate 4-8 ml per hour, patient-controlled analgesia morphine 1mg bolus, lockout 15 minutes, maximum 4mg per hour. Additional bolus dose of 4ml ropivacaine 0.1% will be administered every 30 min if VAS pain score at rest exceed 4. After two top-up bolus doses of 4ml ropivacaine 0.1% , if VAS pain score at rest still exceed 4, the patient will receive 2mg morphine every 15 minutes until VAS score less than 4 The patient will be monitored for vital signs, pain scores, the level of sensory block, opioids consumption, pain site, other adverse effect of opioids such as respiratory depression, sedation. The patient is also monitored for other signs and symptoms associated with nerve injuries or epidural hematoma such severe back pain, radicular pain, numbness, loss of sensation below the level of epidural catheter placement, paralysis or limb motor weakness.",[243],"First-attempt Success Rate of Real-time Ultrasound-guided Thoracic Epidural Catheter Placement",[245],"Real-time ultrasound guided thoracic epidural catheter placement","2025-07-27",{"date":248,"type":40},"2025-08-03",{"date":250,"type":40},"2025-05-23",{"date":252,"type":20},"2027-04-01",{"name":46,"class":47},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},"100531615","comparison-of-laparoscopic-and-open-total-gastrectomy-for-locally-advanced-gastric-cancer-100531615","NCT06202105","Comparison of Laparoscopic and Open Total Gastrectomy for Locally Advanced Gastric Cancer","Comparison of Laparoscopic Versus Open Total Gastrectomy for Locally Advanced Gastric Cancer: a Prospective Randomized Control Trial","LOTA","Inclusion Criteria:\n\n* Pathologic finding by gastric endoscopy: confirmed gastric adenocarcinoma\n* Age: 18 - 80 year old\n* Tumor required total gastrectomy for radical treatment\n* Preoperative cancer stage (CT scan stage): cT2-4aNanyM0\n* ASA score: ≤ 3\n* Informed consent patients (explanation about our clinical trials is provided to the patients or patrons, if patient is not available)\n\nExclusion Criteria:\n\n* Concurrent cancer or patient who was treated due to other cancer before the patient was diagnosed gastric cancer\n* Bulky lymph node andd\u002For Para-aortic lymph node metastasis\n* Combined esophagectomy due to invading to the esophagus\n* Pregnant patient","80 Years",{"count":264,"type":20},210,[23],"Evidence of implementation of laparoscopic total gastrectomy (LTG) for locally advanced gastric cancer (GC) remains inadequate. This study aimed to compare short- and mid-term outcomes of LTG versus open total gastrectomy (OTG) for cT2-4a GC.",[193],"2024-12-30",{"date":270,"type":40},"2025-01-01",{"date":272,"type":40},"2024-08-02",{"date":274,"type":20},"2032-08-02",{"name":46,"class":47},3,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":262,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":48},"100465716","billroth-ii-modified-versus-roux-en-y-after-distal-gastrectomy-for-gastric-cancer-100465716","NCT05344339","Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer","Billroth-II Modified and Roux-en-Y Reconstruction After Distal Gastrectomy for Gastric Cancer: an Open-label Randomized Control Trial","Inclusion Criteria:\n\n* Patients confirmed with gastric cancer\n* Indicated for radical distal gastrectomy (cT1 to cT4a, any N, M0; according to AJCC\u002FUICC 8th TNM staging for gastric cancer)\n* Age from 18- to 80-year-old\n* Agreed to participate in study with written inform consent\n\nExclusion Criteria:\n\n* Pregnant patients\n* An American Society of Anesthesiology (ASA) score of higher than 4\n* Concurrent cancer or history of previous other cancers\n* Previous gastrectomy\n* Complications including bleeding, perforation required emergency gastrectomy",{"count":285,"type":20},320,[23],"There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy.\n\nHypothesis: Billroth-II modified method is non-inferior to Roux-en-Y method in terms of reducing reflux esophagitis after distal gastrectomy for gastric cancer patients.",[193,289],"Distal Gastrectomy",[193,291,292,293,294],"Distal gastrectomy","Reconstruction","Gastric adenocarcinoma","Roux-en-Y",{"date":270,"type":40},{"date":297,"type":40},"2022-10-08",{"date":299,"type":20},"2028-12-31",{"name":46,"class":47},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":308,"targetDuration":310,"studyType":112,"phases":4,"briefSummary":311,"conditions":312,"keywords":316,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":48},"100555782","demographic-clinical-biological-treatment-characteristics-and-cardiovascular-events-of-patients-with-heart-failure-in-vietnam-a-multicenter-prospective-observational-study-100555782","NCT06516562","Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study","MCR-HF","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* Diagnosed with heart failure at the time of discharge\n* Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%\n\nExclusion Criteria:\n\n* Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.)\n* Patients do not reside in Vietnam after discharge",{"count":309,"type":20},2500,"12 Months","Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.",[313,314,315],"Heart Failure","Heart Failure With Reduced Ejection Fraction","Heart Failure With Mid Range Ejection Fraction",[317,318,319,320,321,322,323],"Patient registry","Heart failure","Prospective Observational Study","Demographic","Treatment characteristics","Prognosis","MACE","2024-12-03",{"date":326,"type":40},"2024-12-06",{"date":328,"type":40},"2023-08-01",{"date":330,"type":20},"2028-06-01",{"name":46,"class":47},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":349,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":48},"100565941","efficacy-and-safety-of-shortening-dual-antiplatelet-therapy-duration-with-ivus-guidance-in-pci-patients-100565941","NCT06648720","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients: a Multicenter, Randomized Controlled Trial","SHORTDAPT","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n* Patients with the following clinical indications for PCI:\n\n  * Unstable Angina: Prolonged chest pain at rest, new-onset angina within the past 2 months, or increasing frequency\u002Fseverity of angina attacks.\n  * Acute Myocardial Infarction (MI): With or without ST-elevation.\n  * Chronic Coronary Syndrome: Requiring coronary revascularization.\n* Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n* Neurological Complications: Stroke or any permanent neurological deficits within the last 3 months.\n* Coronary Artery Bypass Graft Surgery: History of CABG surgery.\n* Planned Surgery: Patients who have surgeries planned within the next 12 months.\n* Severe Chronic Kidney Disease: Patients with an estimated glomerular filtration rate (eGFR) of less than 20 ml\u002Fmin\u002F1.73 m² or patients on dialysis.\n* Chronic Anticoagulation Therapy: Patients requiring chronic oral anticoagulation (e.g., warfarin, DOACs) beyond DAPT.\n* Thrombocytopenia: Platelet count less than 100,000\u002Fmm³.\n* Contraindications to Antiplatelet Therapy: Allergy or intolerance to aspirin or P2Y12 inhibitors.\n* Liver Disease: Patients with cirrhosis or significant liver dysfunction.\n* Limited Life Expectancy: Patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n* Other Medical Conditions: Any condition that might interfere with adherence to the study protocol or follow-up schedule.",{"count":341,"type":20},3566,[23],"This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI) guided by intravascular ultrasound (IVUS). The main outcomes measured will include major adverse cardiovascular and cerebrovascular events (NACCE), bleeding events, and target vessel failure (TVF). The goal is to evaluate whether a shorter duration of DAPT is non-inferior to the standard 12-month regimen in preventing ischemic events while reducing the incidence of bleeding.",[345,346,347,348],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)","Intravascular Ultrasound","Dual Antiplatelet Therapy",[350,351,352,345],"Shortening DAPT duration","Intravascular Ultrasound (IVUS)","Percutaenous Coronary Intervention (PCI)","2024-10-16",{"date":355,"type":40},"2024-10-18",{"date":357,"type":20},"2025-03-01",{"date":359,"type":20},"2029-03-01",{"name":46,"class":47},{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":377,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":385,"locationsCount":48},"100564203","efficacy-of-lipid-lowering-therapy-based-on-apolipoprotein-b-versus-ldl-cholesterol-levels-in-patients-undergoing-percutaneous-coronary-intervention-100564203","NCT06626126","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial","ApoB-guidedLLT","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n3. Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n3. Liver Disease: patients with cirrhosis or significant liver dysfunction.\n4. Patients with contraindication to statin or other lipid-lowering therapy.\n5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).",{"count":370,"type":20},1448,[23],"This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.",[345,374,375,376],"Percutaneous Coronary Intervention","LDL-cholesterol","Lipid Metabolism Disorders",[367,378,379,380],"PCI","Coronary artery disease","lipid lowering therapy","2024-10-13",{"date":353,"type":40},{"date":270,"type":20},{"date":228,"type":20},{"name":46,"class":47},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":393,"targetDuration":395,"studyType":112,"phases":4,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":48},"100521603","the-percutaneous-coronary-intervention-registry-in-university-medical-center-of-ho-chi-minh-city-100521603","NCT06071741","The Percutaneous Coronary Intervention Registry in University Medical Center of Ho Chi Minh City","UMC-PCI","Inclusion Criteria:\n\n* All patients undergoing any PCI procedure(s) in given timeframe will be included in this registry\n\nExclusion Criteria:\n\n* No informed consent",{"count":394,"type":20},3600,"5 Years","* This is a hospital-based registry study that will be to describe clinical and paraclinical features, procedural-related characteristics, short and long-term outcomes, hospital costs of patients undergoing percutaneous coronary intervention (PCI) at University Medical Center of Ho Chi Minh City (UMC), together with investigating predictors for patients' adverse clinical outcomes.\n* The specific objectives of this study are:\n\n  * To validate a framework\u002Fmodel of PCI registry in UMC\n  * To investigate the demographic, clinical of cardiovascular diseases and procedural characteristics of patient undergoing PCI in UMC\n  * To investigate the procedural success, in-hospital adverse events and patient outcomes at one-month, three-month, twelve-month, three-year and five-year follow-up after PCI in UMC\n  * To estimate in-hospital and procedural costs associated with PCI in UMC\n  * To develop a prognostic prediction model for patients after PCI in UMC",[398],"Coronary Artery Disease",[374,400,401,398],"Registry","Vietnam","2024-05-20",{"date":404,"type":40},"2024-05-22",{"date":406,"type":40},"2023-03-01",{"date":408,"type":20},"2031-03-01",{"name":46,"class":47},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":56,"minAge":417,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":48},"100547151","plaque-characteristics-predict-recurrent-stroke-in-mca-stroke-patients-100547151","NCT06404242","Plaque Characteristics Predict Recurrent Stroke in MCA Stroke Patients","Plaque Characteristics From Vessel Wall Magnetic Resonance Imaging Predict Recurrent Stroke in Ischemic Stroke Patients Due to Middle Cerebral Artery Stenosis","Inclusion Criteria:\n\n* Patients who had a first-time ischemic stroke due to MCA atherosclerosis stenosis more than 50% and admitted to our hospital within 7 days after onset.\n* Patients are more than 45 years old.\n* Patients had HR-MRI and have done the full stroke workup (including carotid duplex scanning, fasting lipid profile, Holter ECG 24 hours, cardiac ultrasound,...)\n\nExclusion Criteria:\n\n* Patients also have stenosis of the carotid artery (more than 50%) on the same side of ischemic stroke.\n* Patients also have an ischemic stroke in territories other than MCA territory.\n* Patients had any characteristics that suggested other causes for their stenosis, including moyamoya, dissection, and inflammation on their MRI and HR-MRI.\n* Patients with evidence suggestive of cardioembolism (Atrial fibrillation, decreased EF \\\u003C50%, recent heart attack in 3 weeks, rheumatic valvular heart disease, dilated cardiopathy, sick sinus syndrome, infective endocarditis).\n* Any signs suggestive of autoimmune disease or increased coagulation state.\n* Patients with severe concomitant disease could affect the 6-month follow-up of the patients.","45 Years","100 Years",{"count":420,"type":20},125,"The epidemiology of TOAST classification in Asian patients seems to differ due to the higher rates of large-artery atherosclerosis. The complex pathology of atherosclerosis could lead to recurrent stroke, including shear stress on the endothelium, disturbance of the flow, occlusion at the origin of the perforating artery, and other complications (plaque inflammation, plaque hemorrhage, plaque rupture) that could lead to stroke and recurrent stroke. Therefore, The exact determination of the etiology of stroke due to atherosclerosis is the most critical factor for treatment and prognostic. On the other hand, HR-MRI could be a useful imaging modality to evaluate the characteristics of plaque in stroke patients due to atherosclerosis stenosis, which will help us find out the etiology of stroke. Previous studies have demonstrated its prognosis value in predicting recurrent stroke in the same vascular territory. The investigators hypothesize that with an appropriate evaluation, HR-MRI could help to predict recurrent stroke in the same vascular territory in patients with high-risk plaque characteristics on HR-MRI. These findings could contribute to individual treatment according to etiology.\n\nThe investigators intend to conduct a study to determine the correlation between plaque characteristics and recurrent stroke in the same vascular territory in ischemic stroke patients due to middle cerebral artery stenosis.",[423,424],"Stroke, Ischemic","Atherosclerosis, Cerebral","2024-05-04",{"date":427,"type":40},"2024-05-08",{"date":429,"type":40},"2024-04-01",{"date":431,"type":20},"2026-06",{"name":46,"class":47},""]